GlobeNewsWire
05 Aug 2026, 00:50 UTC · 2h ago
Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
05 Aug 2026, 00:50 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Attovia Therapeutics priced its upsized IPO of 17 million shares at $17.00 per share, expecting gross proceeds of $289 million. — The successful raising of significant capital provides the necessary runway for a clinical-stage biotech to fund its drug development pipeline.
+0.60Attovia Therapeutics will begin trading on the Nasdaq Global Market under the symbol 'ATTO' on August 5, 2026. — Public listing provides liquidity and market valuation, though the date itself is a procedural milestone.
+0.20The company is developing a pipeline including ATTO-1310 for pruritic diseases, ATTO-2306 for atopic dermatitis, and ATTO-1091 for inflammatory bowel disease. — The breadth of the pipeline suggests diversification of risk, though no clinical data was provided in the announcement.
+0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company successfully priced an upsized initial public offering, raising approximately $289 million.
Serving as a joint book-running manager for the IPO provides fee-based revenue.
Serving as a joint book-running manager for the IPO provides fee-based revenue.
Serving as a joint book-running manager for the IPO provides fee-based revenue.
[a_to_b] Citigroup is acting as a joint book-running manager for Attovia's IPO.
[a_to_b] Morgan Stanley is acting as a joint book-running manager for Attovia's IPO.
[a_to_b] RBC Capital Markets is acting as a joint book-running manager for Attovia's IPO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
9h ago
